TCEP treatment reduces proteolytic activity of BoNT/B in human neuronal SHSY-5Y cells

Journal of Cellular Biochemistry

Volumn 107, Issue 5, 2009, Pages 1021-1030

  Shi, Xuerong ^a   Garcia, Gregory E ^a   Neill, Roger J ^a   Gordon, Richard K ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

BoNT; Botulinum neurotoxin; Synaptobrevin 2; TCEP; VAMP 2

Indexed keywords

BOTULINUM TOXIN B; HYDROXYUREA; NORADRENALIN; PROTEINASE; REDUCING AGENT; SNARE PROTEIN; SYNAPTOBREVIN 2; TRIS(2 CARBOXYETHYL)PHOSPHINE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISULFIDE BOND; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HEAVY CHAIN; HUMAN; HUMAN CELL; LIGHT CHAIN; NERVE CELL; NEUROPROTECTION; NORADRENALIN RELEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHSY 5Y CELL;

BOTULINUM TOXINS; CELL LINE, TUMOR; CELL SURVIVAL; DISULFIDES; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; HUMANS; HYDROXYUREA; NEURONS; NOREPINEPHRINE; OXIDATION-REDUCTION; PHOSPHINES; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN SUBUNITS; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 67749111568     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22205     Document Type: Article

References (50)

1. Adragna NC, Fonseca P, Lauf PK. 1994. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 83(2):553-560.
2. Agnew BJ, Murray D, Patton WF. 2004. A rapid solid-phase fluorescencebased protein assay for quantitation of protein electrophoresis samples containing detergents, chaotropes, dyes, and reducing agents. Electrophoresis 25(15):2478-2485.
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. 2001. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285(8):1059-1070.
4. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. 2006. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354(5):462-471.
5. Atlas RM. 1998. The medical threat of biological weapons. Crit Rev Microbiol 24(3):157-168.
6. Bandyopadhyay S, Clark AW, DasGupta BR, Sathyamoorthy V. 1987. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J Biol Chem 262(6):2660-2663.
7. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL. 2005. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 11(10): 1578-1583.
8. Bingham JP, Broxton NM, Livett BG, Down JG, Jones A, Moczydlowski EG. 2005. Optimizing the connectivity in disulfide-rich peptides: Alpha-conotoxin SII as a case study. Anal Biochem 338(1):48-61.
9. Cherington M. 1998. Clinical spectrum of botulism. Muscle Nerve 21(6):701-710.
10. Chinnasamy G, Rampitsch C. 2006. Efficient solubilization buffers for two-dimensional gel electrophoresis of acidic and basic proteins extracted from wheat seeds. Biochim Biophys Acta 1764(4):641-644.
11. Cleland WW. 1964. Dithiothreitol, a new protective reagent for SH groups. Biochemistry 3:480-482.
12. Cline DJ, Redding SE, Brohawn SG, Psathas JN, Schneider JP, Thorpe C. 2004. New water-soluble phosphines as reductants of peptide and protein disulfide bonds: Reactivity and membrane permeability. Biochemistry 43(48):15195-15203.
13. Collins KD. 1997. Charge density-dependent strength of hydration and biological structure. Biophys J 72(1):65-76.
14. Collins MD, East AK. 1998. Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins. J Appl Microbiol 84(1):5-17.
15. DasGupta BR. 1990. Structure and biological activity of botulinum neurotoxin. J Physiol (Paris) 84(3):220-228.
16. Deloye F, Doussau F, Poulain B. 1997. Action mechanisms of botulinum neurotoxins and tetanus neurotoxins. C R Seances Soc Biol Fil 191(3):433-450.
17. Doucette PA, Whitson LJ, Cao X, Schirf V, Demeler B, Valentine JS, Hansen JC, Hart PJ. 2004. Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J Biol Chem 279(52):54558-54566.
18. Fischer A, Montal M. 2007. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282(40):29604-29611.
19. Getz EB, Xiao M, Chakrabarty T, Cooke R, Selvin PR. 1999. A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry. Anal Biochem 273(1):73-80.
20. Gill DM. 1982. Bacterial toxins: A table of lethal amounts. Microbiol Rev 46(1):86-94.
21. Gray WR. 1993. Disulfide structures of highly bridged peptides: A new strategy for analysis. Protein Sci 2(10):1732-1748.
22. Hallsworth JE, Heim S, Timmis KN. 2003. Chaotropic solutes cause water stress in Pseudomonas putida. Environ Microbiol 5(12):1270-1280.
23. Han JC, Han GY. 1994. A procedure for quantitative determination of tris(2-carboxyethyl) phosphine, an odorless reducing agent more stable and effective than dithiothreitol. Anal Biochem 220(1):5-10.
24. Honer WG, Falkai P, Bayer TA, Xie J, Hu L, Li HY, Arango V, Mann JJ, Dwork AJ, Trimble WS. 2002. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex 12(4):349-356.
25. Humeau Y, Doussau F, Grant NJ, Poulain B. 2000. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82(5):427-446.
26. Johnson CA, Forster TH, Winterford CM, Allan DJ. 1992. Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt's lymphoma cell line. Biochim Biophys Acta 1136(1):1-4.
27. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10):898-902.
28. Moelbert S, Normand B, De Los Rios P. 2004. Kosmotropes and chaotropes: Modelling preferential exclusion, binding and aggregate stability. Biophys Chem 112(1):45-57.
29. Montecucco C, Schiavo G. 1994. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13(1):1-8.
30. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63.
31. Murphy NP, Ball SG, Vaughan PF. 1991. The effect of calcium channel antagonists on the release of [3H] noradrenaline in the human neuroblastoma, SH-SY5Y. Neurosci Lett 129(2):229-232.
32. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, Schmidt JJ, Pang YP. 2006. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14(2):395-408.
33. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. 1999. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354(1381):259-268.
34. Puhar A, Johnson EA, Rossetto O, Montecucco C. 2004. Comparison of the pH-induced conformational change of different clostridial neurotoxins. Biochem and Biophys Res Commun 319(1):66-71.
35. Royer CA. 1995. Fluorescence spectroscopy. Methods Mol Biol 40:65-89.
36. Ruegg UT, Rudinger J. 1977. Cleavage of disulfide bonds in proteins. Methods Enzymol 47:111-116.
37. Sathyamoorthy V, DasGupta BR. 1985. Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. J Biol Chem 260(19):10461-10466.
38. Schägger H, von Jagow G. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166(2):368-379.
39. Schiavo G, Papini E, Genna G, Montecucco C. 1990. An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun 58(12):4136-4141.
40. Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol Rev 80(2):717-766.
41. Servent D, Winckler-Dietrich V, Hu HY, Kessler P, Drevet P, Bertrand D, Ménez A. 1997. Only snake curaremimetic toxins with a fifth disulfide bond have high affinity for the neuronal alpha7 nicotinic receptor. J Biol Chem 272(39):24279-24286.
42. Shi X, Garcia GE, Nambiar MP, Gordon RK. 2008. Un-nicked BoNT/B activity in human SHSY-5Y neuronal cells. J Cell Biochem 105(1):129-135.
43. Simpson LL. 1979. The action of botulinal toxin. Rev Infect Dis 1(4):656-662.
44. Simpson LL. 2004. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167-193.
45. Simpson LL, Maksymowych AB, Park JB, Bora RS. 2004. The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 308(3):857-864.
46. Smith LA, Rusnak JM. 2007. Botulinum neurotoxin vaccines: Past, present, and future. Crit Rev Immunol 27(4):303-318.
47. Vincent D, Wheatley MD, Cramer GR. 2006. Optimization of protein extraction and solubilization for mature grape berry clusters. Electrophoresis 27(9):1853-1865.
48. Willis B, Eubanks LM, Dickerson TJ, Janda KD. 2008. The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl 47(44):8360-8379.
49. Wright HT, Robertus JD. 1987. The intersubunit disulfide bridge of ricin is essential for cytotoxicity. Arch Biochem Biophys 256:280-284.
50. Zuniga JE, Schmidt JJ, Fenn T, Burnett JC, Araç D, Gussio R, Stafford RG, Badie SS, Bavari S, Brunger AT. 2008. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 16(10):1588-1597.